Securitization of Pharmaceutical/Biotech IP - Intangible Asset-backed Securities

Dear Friends,

I am conducting some research for a paper exploring the potential for large-scale securitization of pharmaceutical/biotech IP and their role in forming an alternative funding method for small to mid-cap pharma.

If anyone works (or knows someone who works) in/with securities, derivatives, structured products and special purpose vehicles I would greatly appreciate the chance to PM them or have them PM to gather more information.

If privacy is a concern for anyone, names (and if need be, firm names) will be omitted.

Thank you in advance

 

hey, are you still in the space? I'm an An1 in securitization and am thinking of lateraling to IB as it seems like there are no transferrable skills to the buyside (I don't have a quant/math/programming background so all the structuring/break-even analysis, Intex, etc. is done by someone else). I also focus on prime assets (I'm in Canada), so I don't feel like I'm learning too much. I've tried to dig around for Intex courses online or other securitization cashflow modelling courses but have no luck. If you have any resources to share, or have advice on what I should do, I'd appreciate it!

 
Most Helpful

This is probably too late to be helpful, and I don't know that my experience is directly relevant, but I have some experience with royalty financing funds if that is at all relevant? I interviewed with one of the bigger royalty funds several years back when they were first emerging (final round but no offer), and a couple portfolio companies of the fund I worked at did some royalty financing deals. My takeaway back then 2011-2014 is that they were comparable to venture debt in terms of total cost of capital, haven't seen as many deals in the current market, maybe bc capital is just more abundant now.

Anyway I think it's a pretty interesting topic intellectually and I'm sure there are some cool opportunities out there, so would love to hear what you found

https://www.baybridgebio.com/
 

Quod quisquam molestiae sint. Repellendus eveniet quo et. Cum molestiae libero sequi consectetur modi incidunt esse. Rerum quibusdam accusantium sint sunt recusandae dolor minima.

Career Advancement Opportunities

April 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. New 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 03 97.1%

Overall Employee Satisfaction

April 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

April 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

April 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (19) $385
  • Associates (87) $260
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (66) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (146) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
Betsy Massar's picture
Betsy Massar
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
kanon's picture
kanon
98.9
6
CompBanker's picture
CompBanker
98.9
7
dosk17's picture
dosk17
98.9
8
GameTheory's picture
GameTheory
98.9
9
numi's picture
numi
98.8
10
Kenny_Powers_CFA's picture
Kenny_Powers_CFA
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”